- Home
- CTVA vs KVUE Comparison
CTVA vs KVUE Comparison
Compare CTVA & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTVA
- KVUE
- Stock Information
- Founded
- CTVA 2018
- KVUE 2022
- Country
- CTVA United States
- KVUE United States
- Employees
- CTVA N/A
- KVUE N/A
- Industry
- CTVA Farming/Seeds/Milling
- KVUE Specialty Chemicals
- Sector
- CTVA Consumer Staples
- KVUE Consumer Discretionary
- Exchange
- CTVA Nasdaq
- KVUE Nasdaq
- Market Cap
- CTVA 41.1B
- KVUE 45.7B
- IPO Year
- CTVA N/A
- KVUE 2023
- Fundamental
- Price
- CTVA $55.19
- KVUE $23.83
- Analyst Decision
- CTVA Buy
- KVUE Buy
- Analyst Count
- CTVA 20
- KVUE 12
- Target Price
- CTVA $63.50
- KVUE $22.64
- AVG Volume (30 Days)
- CTVA 3.3M
- KVUE 17.3M
- Earning Date
- CTVA 11-06-2024
- KVUE 11-07-2024
- Dividend Yield
- CTVA 1.23%
- KVUE 3.44%
- EPS Growth
- CTVA N/A
- KVUE N/A
- EPS
- CTVA 0.98
- KVUE 0.55
- Revenue
- CTVA $16,637,000,000.00
- KVUE $15,459,000,000.00
- Revenue This Year
- CTVA $1.61
- KVUE $3.35
- Revenue Next Year
- CTVA $4.04
- KVUE $3.50
- P/E Ratio
- CTVA $58.32
- KVUE $43.10
- Revenue Growth
- CTVA N/A
- KVUE N/A
- 52 Week Low
- CTVA $43.89
- KVUE $17.67
- 52 Week High
- CTVA $63.75
- KVUE $24.13
- Technical
- Relative Strength Index (RSI)
- CTVA 31.64
- KVUE 61.37
- Support Level
- CTVA $57.00
- KVUE $23.04
- Resistance Level
- CTVA $59.54
- KVUE $23.95
- Average True Range (ATR)
- CTVA 1.33
- KVUE 0.63
- MACD
- CTVA -0.66
- KVUE 0.07
- Stochastic Oscillator
- CTVA 0.06
- KVUE 85.85
About CTVA Corteva Inc.
Corteva is an agricultural inputs pure play that was formed in 2019 when it was spun off from DowDuPont. The company is a leader in the development of new seed and crop protection products. Seeds generate the majority of profits with the remainder coming from crop protection products. Corteva operates globally, but around half of revenue comes from North America.
About KVUE Kenvue Inc.
Kenvue is the world's largest pure-play consumer health company by sales, generating $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio includes a wide array of some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and ever-changing consumer preferences, many of Kenvue's brands are the global leader in their respective segment thanks to their strong brand power.